06667 美因基因
MEGA GENOMICS
MEGA GENOMICS
| Listing Date | 2022/06/22 |
| Listing Price | 18.000 |
Quote
Subscription Result
- Subscription Rate9.62x
- Guarantee One Lot Size20 lot
- One Lot Success Rate10.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Mega Genomics is a leading genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services.
The Group recorded with an average of over 246,000 tests performed per month in 2021. According to Frost & Sullivan, it is the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered. Also, it was the largest genetic testing platform for cancer screening in China as measured by the number of tests administered in 2020.
The Group is a genetic testing company in China with integrated capabilities that cover the full cycle of upstream, midstream and downstream segments. The upstream segment business involves technologies developed by in-house research and development team and cooperation with third-party partners. Its research and development efforts currently focus on the development of LDT services and IVD products. The midstream segment business encompasses an advanced and comprehensive genetic testing technology platform. Its current testing capacity is up to 50,000 tests per day, which is the largest in industry.
The downstream segment business encompasses an extensive sales and marketing network. As of December 31, 2021, it covered over 1,400 healthcare institutions in more than 340 cities in China, and health checkup centers accounted for approximately 57% of institutional customers.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 11.96M shares |
| No. of International Offer Shares | 10.77M shares |
| No. of HK Offer Shares | 1.20M shares |
| Offer Price | $18.00 - $22.00 |
| Stock Code | 6667 |
| Sponsor(s) | China Securities (International) Corporate Finance Company Limited |
| Underwriter(s) | China Securities (International) Corporate Finance Company Limited, China Merchants Securities (HK) Co., Limited, Zhongtai International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Livermore Holdings Limited, Guotai Junan Securities (Hong Kong) Limited |
TIME TABLE
| Application Period | Jun 10 (Fri) - noon, Jun 15 (Wed) |
| Price Determination Date | Jun 15 (Wed) |
| Result Announcement Date | On or before Jun 21 (Tue) |
| Result Announcement Date | On or before Jun 21 (Tue) |
| Dealings in Shares commence on | Jun 22, 2022. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $18.00 - $22.00 |
| Capitalization | 4.30B - 5.30B |
| NAV / share ($) | $4.29 - $4.48 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 20.0, the net proceeds raised would be HKD 190.10M, of which |
| 30% : Sales, marketing and commercialization of consumer genetic testing and cancer screening services and products. |
| 25% : Invested in research and development of services and products |
| 20% : Increasing or expanding testing capability and capacity |
| 15% : Investing or acquiring attractive technology or testing related companies that are complementary and synergistic with existing businesses. |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).